All Stories

  1. Cdc42 regulates cranial suture morphogenesis and ossification
  2. Secondary Hyperparathyroidism: Pathogenesis and Latest Treatment
  3. Nephronectin Expression is Inhibited by Inorganic Phosphate in Osteoblasts
  4. FGF-2 suppresses expression of nephronectin via JNK and PI3K pathways
  5. IL-1β suppresses nephronectin expression in osteoblasts via ERK1/2 and JNK
  6. Erratum to: The cardiothoracic ratio and all-cause and cardiovascular disease mortality in patients undergoing maintenance hemodialysis: results of the MBD-5D study
  7. RAS Inhibitor Is Not Associated With Cardiovascular Benefits in Patients Undergoing Hemodialysis in Japan
  8. Erratum to: The cardiothoracic ratio and all-cause and cardiovascular disease mortality in patients undergoing maintenance hemodialysis: results of the MBD-5D study
  9. The cardiothoracic ratio and all-cause and cardiovascular disease mortality in patients undergoing maintenance hemodialysis: results of the MBD-5D study
  10. Cardiac effect of vitamin D receptor modulators in uremic rats
  11. What are the Newer Applications for Therapeutic Apheresis in Nephrology?
  12. Design and baseline characteristics of the LANDMARK study
  13. A sodium-glucose co-transporter 2 inhibitor empagliflozin prevents abnormality of circadian rhythm of blood pressure in salt-treated obese rats
  14. Myocardial SPECT Images in Incident Hemodialysis Patients Without Ischemic Heart Disease
  15. False-positive Results Obtained for Immunoglobulin M Antibody Tests of Cerebrospinal Fluid for Herpes Simplex Virus in a Patient with Varicella Zoster Virus Encephalitis
  16. Therapeutic Efficacy of Leukocytapheresis in a Pregnant Woman with Refractory Adult-onset Still's Disease
  17. Preface
  18. Active vitamin D analogs, maxacalcitol and alfacalcidol, as maintenance therapy for mild secondary hyperparathyroidism in hemodialysis patients – a randomized study
  19. Clinical Uses of 22-Oxacalcitriol
  20. Intravenous Phosphate Loading Increases Fibroblast Growth Factor 23 in Uremic Rats
  21. Activation of paraoxonase 1 after hemodialysis is associated with HDL remodeling and its increase in the HDL2 fraction and VLDL
  22. Correction of hyperphosphatemia suppresses cardiac remodeling in uremic rats
  23. Clinical significance of IgG deposition in the glomerular mesangial area in patients with IgA nephropathy
  24. Vitamin D receptor activators inhibit vascular smooth muscle cell mineralization induced by phosphate and TNF- 
  25. Number of enlarged parathyroid glands might be a predictor of cinacalcet response in advanced secondary hyperparathyroidism
  26. Correlation between Ischaemia-Modified Albumin and Intermediate-Density Lipoprotein in Haemodialysis Patients with End-Stage Renal Disease
  27. Involvement of Matrix Metalloproteinase-2 in the Development of Medial Layer Vascular Calcification in Uremic Rats
  28. Effects of Calcimimetic Combined with an Angiotensin-Converting Enzyme Inhibitor on Uremic Cardiomyopathy Progression
  29. Detection of Peripheral Artery Disease by Duplex Ultrasonography among Hemodialysis Patients
  30. Involvement of Alpha-Klotho and Fibroblast Growth Factor Receptor in the Development of Secondary Hyperparathyroidism
  31. Elastin Degradation Accelerates Phosphate-Induced Mineralization of Vascular Smooth Muscle Cells
  32. Vitamin D and vascular calcification in chronic kidney disease
  33. The free fraction of paraoxonase 1 is not increased in patients with end stage renal disease undergoing hemodialysis
  34. Clinical significance of parathyroid intervention on CKD-MBD management
  35. CKD-MBD: impact on management of kidney disease
  36. Activation of calcium-sensing receptor accelerates apoptosis in hyperplastic parathyroid cells
  37. Acrolein inactivates paraoxonase 1: changes in free acrolein levels after hemodialysis correlate with increases in paraoxonase 1 activity in chronic renal failure patients
  38. Effects of 22-Oxacalcitriol and Calcitriol on PTH Secretion and Bone Mineral Metabolism in a Crossover Trial in Hemodialysis Patients With Secondary Hyperparathyroidism
  39. Paraoxonase-1 concentrations in end-stage renal disease patients increase after hemodialysis: Correlation with low molecular AGE adduct clearance
  40. High free serum acrolein levels in bacterial infection and other disease states associated with oxidative stress: a potential biomarker?
  41. Therapeutic Strategies for Secondary Hyperparathyroidism in Dialysis Patients
  42. Cystic β2-microglobulin amyloidoma in a patient on long-term hemodialysis
  43. Up-regulation of Cbfa1 and Pit-1 in calcified artery of uraemic rats with severe hyperphosphataemia and secondary hyperparathyroidism
  44. Combination Therapy with Sevelamer Hydrochloride and Calcium Carbonate in Japanese Patients with Long-Term Hemodialysis: Alternative Approach for Optimal Mineral Management
  45. Dose-response Study of 22-Oxacalcitriol in Patients with Secondary Hyperparathyroidism
  46. Calcimimetic Compound Upregulates Decreased Calcium-Sensing Receptor Expression Level in Parathyroid Glands of Rats with Chronic Renal Insufficiency
  47. Management of secondary hyperparathyroidism of dialysis patients
  48. Beneficial Effects of Calcimimetics on Progression of Renal Failure and Cardiovascular Risk Factors
  49. New strategies for the treatment of secondary hyperparathyroidism
  50. Combination treatment with an ETA-receptor blocker and an ACE inhibitor is not superior to the respective monotherapies in attenuating chronic transplant vasculopathy in different aorta allotransplantation rat models
  51. Cigarette smoke condensate aggravates renal injury in the renal ablation model
  52. Clinical Effect of Intravenous Calcitriol Administration on Secondary Hyperparathyroidism
  53. Effect of Plasma Exchange on Refractory Hemophagocytic Syndrome Complicated with Myelodysplastic Syndrome
  54. Plasma Exchange for Acquired Hemophilia: A Case Report